{"database": "openregs", "table": "federal_register", "rows": [["E9-18135", "Guidance for Industry on Drug-Induced Liver Injury: Premarketing Clinical Evaluation; Availability", "Notice", "The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled \"Drug-Induced Liver Injury: Premarketing Clinical Evaluation.\" This guidance is intended to assist the pharmaceutical industry and others engaged in new drug development in the assessment of the potential of a drug to cause severe drug-induced liver injury (DILI) during the conduct of premarketing trials. This guidance defines severe DILI as injury that is fatal or requires liver transplantation.", "2009-07-30", 2009, 7, "https://www.federalregister.gov/documents/2009/07/30/E9-18135/guidance-for-industry-on-drug-induced-liver-injury-premarketing-clinical-evaluation-availability", "https://www.govinfo.gov/content/pkg/FR-2009-07-30/pdf/E9-18135.pdf", "Health and Human Services Department; Food and Drug Administration", "221,199", "The Food and Drug Administration (FDA) is announcing the availability of a guidance for industry entitled \"Drug-Induced Liver Injury: Premarketing Clinical Evaluation.\" This guidance is intended to assist the pharmaceutical industry and others engaged...", null]], "columns": ["document_number", "title", "type", "abstract", "publication_date", "pub_year", "pub_month", "html_url", "pdf_url", "agency_names", "agency_ids", "excerpts", "regulation_id_numbers"], "primary_keys": ["document_number"], "primary_key_values": ["E9-18135"], "units": {}, "query_ms": 0.34309690818190575, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}